China’s Hutchmed inks $1.3 B deal with GSK for KRAS-EGFR-antibody conjugate cancer therapy
September 4, 2026 | Friday | News
Hutchmed Limited will be responsible for the global phase I development programme
image credit- shutterstock
Hutchmed (China) has announced that its subsidiary, Hutchmed Limited has entered into an exclusive development and license agreement with a subsidiary of GSK plc, granting the GSK subsidiary worldwide rights excluding Mainland China, Hong Kong, Macau and Taiwan to develop and commercialise HMPL-A830.
Clinical development will initially focus on colorectal, pancreatic and lung cancer indications. The agreement includes a $110 million upfront payment and potential development, regulatory and commercial milestone payments, for up to a total of $1.295 billion, and royalties on net sales.
This first-in-class drug candidate, an Antibody-Targeted Therapy Conjugate (ATTC), comprises a highly selective and potent Kirsten rat sarcoma (KRAS) small molecule inhibitor payload conjugated to an anti-epidermal growth factor receptor (EGFR) antibody. An ATTC enables tumour-selective activity of potent, cell-killing payloads by leveraging antibody-guided therapy.
Colorectal, lung, and pancreatic cancers have the highest incidence of patients with KRAS-altered tumours, who often lack a safe and durable KRAS therapy. HMPL-A830 is designed to address this need by delivering a KRAS inhibitor directly to EGFR-expressing tumours, while simultaneously blocking EGFR and KRAS signaling to enhance efficacy, durability, and tolerability.
Under the terms of the agreement, Hutchmed Limited will be responsible for the global phase I development programme, which is expected to start in the second half of 2026.